Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Tegoprazan, EAPA115, and RAPA115 in Healthy Volunteers
NCT04231136Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoint: Pharmacodynamic Evaluation (Intragastric pH) at 24 hours. Started Jan 2020; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04231136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231136.